Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BLRX $1.28 0.2700 +26.73%
BDSI $2.70 0.2500 +10.20%
TRIL $15.99 1.3300 +9.07%
NLNK $12.87 0.8600 +7.16%
BLCM $20.57 1.2600 +6.53%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

MNKD $0.61 -0.0664 -9.75%
MRTX $5.88 -0.5800 -8.98%
CALA $3.00 -0.1800 -5.66%
GALT $2.73 -0.1400 -4.88%
MTP $3.11 -0.1400 -4.31%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications

(The Business Journal) Sept 7, 2016 - BioLineRx Ltd. today announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications.
read article 

Gene-editing Method Shrinks Cancer

(BBC News) Sept 6, 2016 - Scientists have used a gene-editing tool to stunt tumour growth in mice.
read article 

New Treatment May Help Those with Rare Immune Cancers

(UNM CCC) Sept 6, 2016 - Clinical trial shows new drug holds promise for treating advanced mastocytosis.
read press release 

Research by NFCR Scientists Reveals New Insights into Treatment Resistance of Metastastic Breast Cancer

(NFCR) Sept 6, 2016 – A prominent physician scientist supported by the National Foundation of Cancer Research (NFCR), Dr. Daniel Haber, and his team at the Massachusetts General Hospital Cancer Center have identified a dynamic gene expression in metastatic breast cancer that may contribute to disease progression and resistance to treatment experienced by many patients.
read press release 

Cancer 'Smoke Detector' Test Can Spot The Disease 10 Years Before Symptoms Appear

(The Telegraph [UK]) Sept 6, 2016 - A revolutionary blood test, which acts like a smoke detector to spot cancer up to 10 years before symptoms appear, could be available within five years.
read article 

New Drug 'Wakes Up' Immune System To Fight One Of Deadliest Cancers

(The Guardian [UK]) Sept 6, 2016 - IMM-101 drug has extended lives of people with metastatic pancreatic cancer and appears to have no side-effects.
read article 

Research Shows it May be Time to Abandon Dreaded Digital Rectal Exam

(Wake Forest Baptist Medical Center|) Sept 6, 2016 - The dreaded finger exam to check for prostate cancer used to be a mainstay of check-ups for older men. With its value now in question, some doctors share the risks and benefits with their patients and let them decide. So, should they or shouldn’t they?
read press release 

Electronic Health Record Data Can Help Determine Highest Risk of Early Death from Chemotherapy in Older Patients with Lymphoma

(NCCN) Sept 7, 2016 - Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment.
read press release 

Cancer Caregivers Experience Unique Burdens Compared With Those Caring for Patients With Other Conditions

(ASCO) Sept 6, 2016 - An analysis of data from more than 1,200 caregivers in the United States finds that cancer caregivers report a higher burden and spend significantly more hours per week caregiving, as opposed to individuals who care for people with other conditions.
read article 

“Mystery Shopper” Study Finds Barriers to Accessing Palliative Care Services at Major Cancer Centers

(ASCO) Sept 6, 2016 - A team of researchers, using a novel approach, found that while many cancer centers offer palliative and supportive care services, patients may face challenges when trying to access them.
read press release 

Early Palliative Care Improves Coping, Quality of Life for Patients With Incurable Cancers

(ASCO) Sept 6, 2016 - A randomized clinical trial found that introducing palliative care shortly after a diagnosis of certain metastatic cancers greatly increases a patient’s coping abilities, as well as overall quality of life.
read press release 

Family Caregivers for Patients With Advanced Cancer Often Experience High Levels of Anxiety, Depression

(ASCO) Sept 6, 2016 - A new multi-state survey shows that nearly one-quarter to one-third of family caregivers of patients with high-mortality cancers experience high levels of depression and anxiety symptoms.
read press release 

Cancer ‘Moonshot’ Panel Names Top 10 Ways To Speed Progress Against The Disease

(Washington Post/To Your Health) Sept 7, 2016 - The Obama administration's "cancer moonshot" took a major step forward Wednesday when a committee of top cancer researchers and patient advocates recommended an ambitious set of scientific goals designed to sharply accelerate progress against the disease.
read article (free registration required) 

FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

(Merck) Sept 7, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016.
read corporate press release 

EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog

(Kaiser Health News) Sept 6, 2016 - Consumers and Congress members pushing for cheaper alternatives to the EpiPen and other high-priced drugs are seeking answers about a stubborn backlog of generic drug applications at the Food and Drug Administration that still stretches almost four years.
read article 

Getting Doctor Lists Right

(Kaiser Health News) Sept 6, 2016 - The law, which took effect July 1, also provides patients with some firepower to fight surprise medical bills that result from directory errors.
read article 

For Every Hour With Patients, Doctors Spend Two Record-Keeping

(Forbes) Sept 6, 2016 - Physicians are spending nearly twice as much time with new electronic health record systems and “desk work” as they are providing medical care to their patients, according to a new study in the Annals of Internal Medicine.
read article 

Medicare Cuts Would Scorch Patients

(San Antonio Express-News) Sept 4, 2016 - Biopharmaceutical companies are hard at work developing medicines to treat melanoma, a lethal and fast-spreading disease. But recent proposed changes to Medicare, the health insurance program for seniors, could put these medications out of the reach of Texans who need them most.
read article 

Blood Cancer Treatment May Age Immune Cells As Much As 30 Years

(UNC Lineberger) Sept 1, 2016 - Researchers led by UNC Lineberger Director Norman Sharpless, MD, and William Wood, MD, uncovered clues that suggest that stem cell transplant is linked to a marked increase in the “molecular age” of these immune cells in a group of patients with blood cancer.
read article 

NCCN Awards 3 Grants to Investigators to Study Bavituximab in Combination with Other Therapeutic Strategies in Various Cancers

(NCCN) Sept 6, 2016 - The NCCN Oncology Research Program has awarded research grants to three investigators to study bavituximab in glioblastoma, head and neck cancer, and hepatocellular carcinoma.
read press release 

MDxHealth Gains Medi-Cal Approval for ConfirmMDx

(4-traders) Sept 6, 2016 - Opens testing access to the largest state-run health plan in the United States.
read article 

BD Submits Pre-Market Approval Application to FDA for BD Onclarity™ HPV Test

(StockWatch) Sept 6, 2016 - BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the BD Onclarity™ HPV Assay, its human papillomavirus (HPV) test.
read article 

ICER Puts Hard-Fought Progress In Non-Small Cell Lung Cancer Treatment At Risk

(PhRMA/The Catalyst blog) Sept 1, 2016 - ICER’s draft evidence report on treatments for NSCLC indicates that they consider these life-changing treatments of low value.
read article 

German Pricing Rules Hit Eisai’s Halaven

(pharmaphorum [UK]) Sept 5, 2016 - Eisai may have to sell its Halaven (eribulin) at rock-bottom prices in its new advanced liposarcoma use in Germany after a cost-effectiveness body found it offered “no additional benefit” compared with standard care.
read article 

NICE Rejects Roche’s Melanoma Combo

(PharmaTimes [UK]) Sept 6, 2016 - Patients in England and Wales with a certain type of advanced skin cancer will not be getting routine access to Roche's Cotellic/Zelboraf combination on the NHS, after it was turned down by the National Institute for Health and Care Excellence.
read article